Evidence-based Products

STUDY CLAIM: 480mcg/mL maitake (Grifola frondosa) D-fraction effectively killed cancer cells in vitro within 24 hours. 500mg maitake SX-fraction positively affected serum glucose levels in five type II diabetes patients within four weeks.

PUBLISHED: Donno S, et al. Anticancer and hypoglycemic effects of polysaccharides in edible and medicinal maitake mushroom [Grifola frondosa (Dicks.: Fr.) SF Gray] Intl J Medicinal Mushrooms 2002;4:185-95.

ABSTRACT: Researchers studied the possible anticancer activity and hypoglycemic action of bioactive polysaccharides in maitake mushroom (Grifola frondosa), namely D-fraction and SX-fraction, on human prostate cancer PC-3 cells in vitro and five type II diabetes patients.

D-fraction at >=480mcg/mL in prostatic cancer PC-3 cells resulted in nearly total cancer cell death within 24 hours. The combination of 60mcg/mL D-fraction and 200 micromolar concentration vitamin C was as effective as 480mcg/mL D-fraction alone, suggesting a synergistic potentiation of D-fraction with vitamin C.

Five patients with type II diabetes under oral medications had improved glycemic levels with G. frondosa polysaccharide caplets (MPCs) containing active SX-fraction in two to four weeks.

POTENTIAL APPLICATIONS: Polysaccharides of G. frondosa may have therapeutic implications in the effective treatment of prostate cancer and type II diabetes.

MORE INFO: Maitake Products Inc
Tel:+1 201 299 0101

STUDY CLAIM: Soyselect, .35 per cent or .7 per cent of soy extract in 72 female rats over 24 weeks, reduced the size of tumours.

PUBLISHED: Gallo D, et al. Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. Breast Cancer Res Treat 2001 Sep;69(2):153-64.

ABSTRACT: Researchers studied three groups of female rats, 24 animals in each group. They fed the animals either a phytoestrogen-free diet alone (control) or the same diet supplemented with .35 per cent or .7 per cent of Soyselect. Treatment started at weaning and continued to the end of the study (24 weeks after tumour-inducing DMBA administration). When the rats were 50 days old, all animals received an oral dose of 80mg/kg DMBA.

The tumours in the rats eating Soyselect took a longer period of time to develop compared with the control group. However, at the end of the study, researchers observed no relevant difference in tumour incidence and multiplicity among the groups. They observed the most significant changes between the control and Soyselect groups, considering tumour dimension and results from histopathologic examination. The latter, in fact, showed a dose-dependent reduction in the percentage of poorly differentiated tumours in treated animals.

POTENTIAL APPLICATIONS: Soyselect can be added to tablets, softgels, hardshells and functional foods.

Tel: +39 02 5740 4620, www.indena.it

STUDY CLAIM: 3g/day AHCC improved the prognosis of postoperative hepatocellular carcinoma (HCC) patients.

PUBLISHED: Matsui Y, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 2002 Jul;37(1):78-86.

ABSTRACT: Although in vitro experiments have shown that AHCC enhances natural killer cell activity, the effects of AHCC in a clinical setting have not been reported. Researchers in the department of surgery, Kansai Medical University, Osaka, Japan, wanted to determine whether AHCC can improve the prognosis of hepatocellular carcinoma (HCC) patients following surgical treatment.

They conducted a prospective cohort study from Feb 1 1992, to Dec 31 2001. They studied 269 consecutive patients with histologically confirmed HCC, all of whom underwent resection of a liver tumour. Researchers examined time-to-treatment failure (disease recurrence or death) and 10 parameters related to liver function after surgery. Of the 269 patients, 113 took 3g/day AHCC orally after undergoing curative surgery. This group had a significantly longer no-recurrence period, with a 95 per cent confidence interval and an increased overall survival rate compared with the control group.

POTENTIAL APPLICATIONS: AHCC is available in 500mg capsules. It may improve the quality of life for patients with cancer, AIDS, hepatitis B and C, and other ailments involving immune dysfunction.

MORE INFO: Quality of Life Labs
Tel: +1 877 YES AHCC, www.q-o-l.com

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.